Astonea Labs Limited
BSE: ASTONEALAB · Pharmaceuticals · sector
Key numbers
Last 12 months to Mar 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Operating profit covered interest 2.7x in the last 12 months.
- Other income was 12% of net profit in the last 12 months.
- No dividend in the last 2 financial years.
- Price ₹323.00 on 2026-10-19: -12.5% from the 52-week high, +173.7% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Quarterly results
| ₹ cr | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|
| Revenue | 50 | 66 | 81 |
| EBITDA | 9 | 5 | 8 |
| OPM % | 17.0% | 8.1% | 9.8% |
| Other income | 0 | 0 | 0 |
| Net profit | 3 | 1 | 3 |
| EPS (₹) | 4.17 | 1.03 | 3.08 |
Consolidated figures where filed. Latest quarter Mar 2026.
Profit & loss (yearly)
| ₹ cr | FY25 | FY26 | TTM |
|---|---|---|---|
| Revenue | 98 | 148 | 148 |
| EBITDA | 15 | 13 | 13 |
| Net profit | 5 | 5 | 5 |
| EPS (₹) | 6.94 | 4.49 | 4.49 |
| Revenue growth | +51.3% | – | |
| Profit growth | -15.5% | – | |
| Dividend / share (₹) | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | – | – | – |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | – (2y) | +103.1% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 11 | 47 |
| Cash & equivalents | 0 | 12 |
| Total assets | 103 | 146 |
| Fixed assets | 25 | 31 |
| Investments | 0 | 6 |
| Inventory | 29 | 34 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | 9 | -14 |
| Cash from investing | -11 | -20 |
| Cash from financing | 2 | 34 |
| Capex | 11 | 14 |
| Free cash flow | -2 | -28 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | 50.0% | 9.7% |
| ROCE % | 100.3% | 19.1% |
| Inventory days | 161 | 125 |
| Working capital days | 30 | 75 |
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| ASTONEALAB | ₹340 cr | 71.9x | 7.3x | 15.8% | 19.1% | 9.1% | – | – |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | ASTONEALAB |
| BSE code | 544409 |
| ISIN | INE0TG901011 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-24 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-19.